Literature DB >> 4718666

Bioassay and relative cytotoxic potency of cyclophosphamide metabolites generated in vitro and in vivo.

N E Sladek.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4718666

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  19 in total

1.  Basic principles in preclinical cancer chemotherapy.

Authors:  N Brock; J Pohl; B Schneider
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

Review 2.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  L B Grochow; M Colvin
Journal:  Clin Pharmacokinet       Date:  1979 Sep-Oct       Impact factor: 6.447

3.  Epstein-Barr virus and brain lymphomas.

Authors:  R M Bashir; F H Hochberg; M X Wei
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

4.  Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test.

Authors:  T Wagner; D Heydrich; T Jork; G Voelcker; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

5.  Carbon tetrachloride-induced increase in the antitumor activity of cyclophosphamide in mice: a pharmacokinetic study.

Authors:  R N Harris; P J Basseches; P L Appel; A M Durski; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

6.  Preclinical pharmacokinetics and stability of isophosphoramide mustard.

Authors:  J J Zheng; K K Chan; F Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Effect of cyclophosphamide in vitro and on vaccinia virus replication in tissue culture.

Authors:  A H Ginsberg; W T Monte; K P Johnson
Journal:  J Virol       Date:  1977-01       Impact factor: 5.103

8.  Metabolism and pharmacokinetics of oral and intravenous ifosfamide.

Authors:  V Kurowski; T Cerny; A Küpfer; T Wagner
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 9.  Comparative activity of ifosfamide and cyclophosphamide.

Authors:  W Brade; S Seeber; K Herdrich
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  General adverse response to cyclophosphamide in Chinese patients with systemic autoimmune diseases in recent decade—a single-center retrospective study.

Authors:  Juan Li; Guowei Dai; Zhuoli Zhang
Journal:  Clin Rheumatol       Date:  2014-07-23       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.